Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations

Future Oncol. 2015;11(16):2251-4. doi: 10.2217/fon.15.134.
No abstract available

Keywords: adverse events; breast cancer; compliance; dosing; everolimus; management; multidisciplinary follow-up; toxicity.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Disease Management
  • Everolimus / administration & dosage
  • Female
  • Humans
  • Medication Adherence
  • Neoplasm Staging
  • Receptor, ErbB-2 / metabolism
  • Receptors, Estrogen / metabolism
  • Receptors, Progesterone / metabolism

Substances

  • Receptors, Estrogen
  • Receptors, Progesterone
  • Everolimus
  • Receptor, ErbB-2